Bausch + Lomb Corporation (NYSE:BLCO) Receives $18.67 Consensus Price Target from Analysts

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have earned an average recommendation of “Hold” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $18.75.

A number of research firms have recently weighed in on BLCO. Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Weiss Ratings upgraded Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 24th. UBS Group started coverage on Bausch + Lomb in a research note on Thursday, July 30th. They issued a “buy” rating and a $21.00 price target for the company. Citigroup upped their price objective on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, HC Wainwright increased their price objective on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $21 price target for Bausch + Lomb (BLCO), signaling confidence in the company’s longer-term value. HC Wainwright Forecasts Strong Price Appreciation for Bausch + Lomb Stock
• Positive Sentiment: The analyst raised projected EPS for the first and second quarters of 2027 to $0.12 and $0.25, respectively, from $0.07 and $0.22. These increases suggest some improvement is expected in parts of the 2027 earnings outlook.
• Neutral Sentiment: HC Wainwright’s updated 2027 quarterly estimates are $0.12 for Q1, $0.25 for Q2, $0.21 for Q3 and $0.31 for Q4, resulting in a full-year forecast of $0.89 per share.
• Negative Sentiment: The firm cut its Q3 2026 EPS estimate to $0.17 from $0.21 and its Q4 estimate to $0.28 from $0.34. Its FY2026 forecast fell to $0.68 from $0.83, below the broader consensus estimate of approximately $0.81.
• Negative Sentiment: Longer-term revisions were also mixed to negative: Q3 2027 EPS was reduced to $0.21 from $0.23, Q4 2027 to $0.31 from $0.41, and FY2027 to $0.89 from $0.93. The reductions point to weaker expected profitability than previously modeled.

Institutional Trading of Bausch + Lomb

Large investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. increased its stake in Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after acquiring an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after purchasing an additional 1,136 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Bausch + Lomb by 67.1% in the 1st quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock valued at $58,000 after purchasing an additional 1,468 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Bausch + Lomb by 31.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after purchasing an additional 1,403 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Bausch + Lomb in the 3rd quarter valued at $170,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Trading Up 0.3%

Shares of BLCO stock opened at $16.73 on Monday. The stock has a 50 day simple moving average of $15.98 and a 200 day simple moving average of $16.41. Bausch + Lomb has a 1 year low of $13.53 and a 1 year high of $18.92. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. The stock has a market cap of $5.98 billion, a P/E ratio of -34.86, a price-to-earnings-growth ratio of 0.54 and a beta of 0.56.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.